

Staging of the intracerebral inclusion body pathology as Parkinson's disease (preclinical and clinical stages)

Journal of Neurology

249, 1-1

DOI: [10.1007/s00415-002-1301-4](https://doi.org/10.1007/s00415-002-1301-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical and neuropathological correlates of Lewy body disease. <i>Acta Neuropathologica</i> , 2003, 106, 188-189.	3.9	15
2	Î±-Synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution—a pilot study. <i>Acta Neuropathologica</i> , 2003, 106, 191-202.	3.9	169
3	Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. <i>Journal of Neural Transmission</i> , 2003, 110, 517-536.	1.4	1,323
4	Constipation in Idiopathic Parkinson's Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 681-686.	0.6	36
5	Biomarkers and Parkinson's disease. <i>Brain</i> , 2004, 127, 1693-1705.	3.7	151
6	Lewy Bodies in the Amygdala. <i>Archives of Neurology</i> , 2004, 61, 1915-9.	4.9	102
7	Olfactory testing in parkinsonism. <i>Lancet Neurology</i> , The, 2004, 3, 393-394.	4.9	18
8	Lewy body-related ?-synucleinopathy in the aged human brain. <i>Journal of Neural Transmission</i> , 2004, 111, 1219-1235.	1.4	243
9	Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. <i>Annals of Nuclear Medicine</i> , 2004, 18, 453-461.	1.2	128
10	Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes. <i>Movement Disorders</i> , 2004, 19, 518-528.	2.2	72
11	L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. <i>Behavioural Brain Research</i> , 2004, 153, 439-446.	1.2	95
12	Genes, proteins, and neurotoxins involved in Parkinson's disease. <i>Progress in Neurobiology</i> , 2004, 73, 151-177.	2.8	162
13	Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 271-282.	2.2	79
15	Pain in Parkinson's disease and multiple sclerosis: Its relation to the medial and lateral pain systems. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 1047-1056.	2.9	81
16	Localization of DJ-1 protein in the murine brain. <i>Cell and Tissue Research</i> , 2005, 322, 503-507.	1.5	24
17	3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy. <i>Synapse</i> , 2005, 55, 148-155.	0.6	15
18	Sensory-Motor Integration in the Medial Medulla. <i>Current Neuropharmacology</i> , 2005, 3, 115-143.	1.4	4
19	Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of Î±-synuclein in the substantia nigra. <i>FASEB Journal</i> , 2005, 19, 1740-1742.	0.2	70

#	ARTICLE	IF	CITATIONS
20	Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 156-162.	0.9	134
21	MORPHOLOGICAL RECOVERY OF THE GRANULE CELLS FROM THE OLFACTORY BULB AFTER THE CESSATION OF ACUTE OZONE EXPOSURE. <i>International Journal of Neuroscience</i> , 2005, 115, 411-421.	0.8	4
22	The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1. <i>Trends in Molecular Medicine</i> , 2005, 11, 488-495.	3.5	49
23	Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using ¹³ C-sodium octanoate breath test. <i>Neuroscience Letters</i> , 2005, 375, 170-173.	1.0	135
24	Lewy bodies in Parkinson's disease: Protectors or perpetrators?. <i>Experimental Neurology</i> , 2005, 195, 1-6.	2.0	24
25	Cognitive Deficits and Psychosis in Parkinson's Disease. <i>CNS Drugs</i> , 2006, 20, 477-505.	2.7	115
26	Small heat shock proteins protect against α -synuclein-induced toxicity and aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2006, 351, 631-638.	1.0	180
27	Abnormal proprioceptive-motor integration contributes to hypometric postural responses of subjects with parkinson's disease. <i>Neuroscience</i> , 2006, 141, 999-1009.	1.1	169
28	Transplanted Human Neural Precursor Cells Migrate Widely but Show no Lesion-Specific Tropism in the 6-Hydroxydopamine Rat Model of Parkinson's Disease. <i>Cell Transplantation</i> , 2006, 15, 579-593.	1.2	15
29	Genetically Engineered Mouse Models of Neurodegenerative Disorders. , 2006, , 371-408.		0
30	Effects of the cholesterol-lowering compound methyl- β -cyclodextrin in models of α -synucleinopathy. <i>Journal of Neurochemistry</i> , 2006, 98, 1032-1045.	2.1	69
31	Neural transplants for parkinson's disease: what are the issues?. <i>Poiesis & Praxis</i> , 2006, 4, 129-143.	0.3	1
32	The parkinson's complex: Parkinsonism is just the tip of the iceberg. <i>Annals of Neurology</i> , 2006, 59, 591-596.	2.8	524
33	The genetics of Parkinson disease: implications for neurological care. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 136-146.	2.7	153
34	Animal models of Parkinson's disease. , 0, , 411-437.		0
35	Cognitive impairment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1182-1187.	0.9	204
36	The Role of Levodopa in the Chronic Neurodegenerative Disorder " Parkinson's Disease. , 2007, , 237-246.		0
37	Protein Aggregation Mechanisms in Synucleinopathies: Commonalities and Differences. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 965-974.	0.9	60

#	ARTICLE	IF	CITATIONS
38	Clinical relevance of rehabilitation programs for patients with idiopathic Parkinson syndrome. II: Symptom-specific therapeutic approaches. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 203-213.	1.1	30
39	Clinical relevance of rehabilitation programs for Parkinson's disease. I: Non-symptom-specific therapeutic approaches. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 195-202.	1.1	10
40	The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. <i>Neuroscience</i> , 2007, 146, 741-755.	1.1	83
42	Non-motor Symptoms of Parkinson's Disease. <i>International Journal of Gerontology</i> , 2007, 1, 53-64.	0.7	44
43	Lewy Body Disorders. , 2007, , 267-343.		4
45	Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2249-2255.	2.2	47
46	Proteomic Identification of Novel Proteins in Cortical Lewy Bodies. <i>Brain Pathology</i> , 2007, 17, 139-145.	2.1	194
47	Nicotinic receptors as CNS targets for Parkinson's disease. <i>Biochemical Pharmacology</i> , 2007, 74, 1224-1234.	2.0	90
48	ICU management of patients with Parkinson's disease or Parkinsonism. <i>Current Anaesthesia and Critical Care</i> , 2007, 18, 227-236.	0.3	9
49	Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: Microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. <i>Experimental Gerontology</i> , 2007, 42, 762-771.	1.2	57
50	Concise Review: Therapeutic Strategies for Parkinson Disease Based on the Modulation of Adult Neurogenesis. <i>Stem Cells</i> , 2007, 25, 263-270.	1.4	79
51	Coaxil (tianeptine) in the treatment of depression in Parkinson's disease. <i>Neuroscience and Behavioral Physiology</i> , 2007, 37, 419-424.	0.2	16
52	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. <i>Journal of Neural Transmission</i> , 2007, 114, 527-537.	1.4	49
53	Olfactory dysfunction in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, IV2-IV7.	1.8	6
55	Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic?. <i>Psychopharmacology</i> , 2008, 199, 303-312.	1.5	60
56	Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. <i>Neurogenetics</i> , 2008, 9, 163-172.	0.7	76
57	Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. <i>Journal of Neural Transmission</i> , 2008, 115, 1385-1392.	1.4	33
58	Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. <i>Acta Neuropathologica</i> , 2008, 115, 445-451.	3.9	116

#	ARTICLE	IF	CITATIONS
59	Evaluation of α -synuclein immunohistochemical methods used by invited experts. <i>Acta Neuropathologica</i> , 2008, 116, 277-288.	3.9	157
60	Alpha-synuclein and its role in metal binding: Relevance to Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2008, 86, 496-503.	1.3	39
61	Olfactory pathogenesis of idiopathic Parkinson disease revisited. <i>Movement Disorders</i> , 2008, 23, 1076-1084.	2.2	73
62	Association of olfactory dysfunction with risk for future Parkinson's disease. <i>Annals of Neurology</i> , 2008, 63, 167-173.	2.8	636
63	A critical evaluation of the Braak staging scheme for Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, 485-491.	2.8	331
64	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy-Related Pathology in the Dementia Patient. <i>Brain Pathology</i> , 2008, 18, 220-224.	2.1	106
65	Extrastriatal monoamine neuron function in Parkinson's disease: An 18F-dopa PET study. <i>Neurobiology of Disease</i> , 2008, 29, 381-390.	2.1	111
66	Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2008, 22, 563-586.	2.7	79
67	Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. <i>Neuroscience</i> , 2008, 154, 1388-1397.	1.1	106
68	Cardiac denervation and dysautonomia in Parkinson's disease: A review of screening techniques. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 524-531.	1.1	19
69	ACTIGRAPHIC EVIDENCE FOR NIGHT-TIME HYPERKINESIA IN PARKINSON'S DISEASE. <i>International Journal of Neuroscience</i> , 2008, 118, 291-310.	0.8	19
70	Procedural learning eliminates specific slowing down of response selection in patients with idiopathic Parkinson syndrome. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2008, 30, 319-326.	0.8	2
71	Progressive Supranuclear Palsy: A Review of Co-existing Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 602-608.	0.3	18
72	Drug Targeting of α -Synuclein Oligomerization in Synucleinopathies. <i>Perspectives in Medicinal Chemistry</i> , 2008, 2, 1177391X0800200.	4.6	3
73	Motor Functions and Dysfunctions of Sleep. , 2009, , 397-435.		18
74	Treatment strategies for nonmotor manifestations of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 773-784.	0.9	10
75	Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity. <i>Journal of Neuroscience</i> , 2009, 29, 8103-8113.	1.7	241
76	Inner Retinal Layer Thinning in Parkinson Disease. <i>JAMA Ophthalmology</i> , 2009, 127, 737.	2.6	261

#	ARTICLE	IF	CITATIONS
77	Molecular Pathology of Lewy Body Diseases. <i>International Journal of Molecular Sciences</i> , 2009, 10, 724-745.	1.8	101
78	Differential DJ-1 gene expression in Parkinson's disease. <i>Neurobiology of Disease</i> , 2009, 36, 393-400.	2.1	42
79	Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: The olfactory and immune system interrelationship. <i>Clinical Immunology</i> , 2009, 130, 235-243.	1.4	73
80	Alterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro- β -carboline. <i>Journal of Neural Transmission</i> , 2009, 116, 1267-1271.	1.4	7
81	Retinopathy in Parkinson disease. <i>Journal of Neural Transmission</i> , 2009, 116, 1493-1501.	1.4	133
82	Olfactory bulb α -synucleinopathy has high specificity and sensitivity for Lewy body disorders. <i>Acta Neuropathologica</i> , 2009, 117, 169-74.	3.9	193
83	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. <i>Acta Neuropathologica</i> , 2009, 117, 613-634.	3.9	553
84	Proteomics in human Parkinson's disease research. <i>Journal of Proteomics</i> , 2009, 73, 10-29.	1.2	98
85	Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing. <i>Neuroscience</i> , 2009, 158, 426-440.	1.1	50
86	The supplementary motor area contributes to the timing of the anticipatory postural adjustment during step initiation in participants with and without Parkinson's disease. <i>Neuroscience</i> , 2009, 164, 877-885.	1.1	198
87	The neuropathological basis for depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 144-148.	1.1	123
88	Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects. <i>Progress in Neurobiology</i> , 2009, 88, 89-103.	2.8	92
89	Calcium(II) selectively induces α -synuclein annular oligomers via interaction with the C-terminal domain. <i>Protein Science</i> , 2009, 13, 3245-3252.	3.1	143
90	Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. <i>NeuroImage</i> , 2009, 47, 1237-1243.	2.1	46
91	Dissecting the potential molecular mechanisms underlying α -synuclein cell-to-cell transfer in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S143-S147.	1.1	81
92	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. <i>Brain</i> , 2009, 132, 2958-2969.	3.7	842
93	OVERVIEW OF COMMON MOVEMENT DISORDERS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 13-48.	0.4	12
94	Diffusion Tensor Imaging in Idiopathic REM Sleep Behavior Disorder Reveals Microstructural Changes in the Brainstem, Substantia Nigra, Olfactory Region, and Other Brain Regions. <i>Sleep</i> , 2010, 33, 767-773.	0.6	175

#	ARTICLE	IF	CITATIONS
95	Can endogenous stem cells be stimulated to repair the degenerating brain? Journal of Pharmacy and Pharmacology, 2010, 56, 1201-1210.	1.2	3
96	Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 537-544.	3.3	35
97	Cardiac sympathetic denervation precedes nigrostriatal loss in the E46K mutation of the α -synuclein gene (SNCA). Clinical Autonomic Research, 2010, 20, 267-269.	1.4	44
98	Are synucleinopathies prion-like disorders?. Lancet Neurology, The, 2010, 9, 1128-1138.	4.9	226
99	Environmental neurotoxin-induced progressive model of parkinsonism in rats. Annals of Neurology, 2010, 68, 70-80.	2.8	62
100	Glycoproteomics in neurodegenerative diseases. Mass Spectrometry Reviews, 2010, 29, 79-125.	2.8	99
101	Evaluation of the Braak staging scheme for Parkinson's disease: Introduction to a panel presentation. Movement Disorders, 2010, 25, S76-7.	2.2	14
102	Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease. Movement Disorders, 2010, 25, 2099-2104.	2.2	53
103	Biopsable Neural Tissues: Toward New Biomarkers for Parkinson's Disease?. Frontiers in Psychiatry, 2010, 1, 128.	1.3	37
104	Basal ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Frontiers in Neuroanatomy, 2010, 4, .	0.9	27
105	Olfactory function and Parkinson's disease in Southern Brazil. Arquivos De Neuro-Psiquiatria, 2010, 68, 252-257.	0.3	22
106	Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated α -synuclein gene mutations precede central nervous system changes. Human Molecular Genetics, 2010, 19, 1633-1650.	1.4	237
107	Functional imaging studies of hyposmia in Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 36-39.	0.3	23
108	Olfactory system pathology as a model of Lewy neurodegenerative disease. Journal of the Neurological Sciences, 2010, 289, 49-54.	0.3	68
109	Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain, 2010, 133, 1747-1754.	3.7	263
110	Current Aspects of Cognitive Neurophysiology of Parkinson Disease: An Introduction. Clinical EEG and Neuroscience, 2010, 41, 68-75.	0.9	2
111	The cholinergic system and Parkinson disease. Behavioural Brain Research, 2011, 221, 564-573.	1.2	432
112	Severe Alterations in Lipid Composition of Frontal Cortex Lipid Rafts from Parkinson's Disease and Incidental Parkinson's Disease. Molecular Medicine, 2011, 17, 1107-1118.	1.9	308

#	ARTICLE	IF	CITATIONS
113	VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-9.	0.6	75
114	Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-13.	0.6	51
115	Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration. <i>Current Medicinal Chemistry</i> , 2011, 18, 2459-2476.	1.2	80
116	A deadly spread: cellular mechanisms of α -synuclein transfer. <i>Cell Death and Differentiation</i> , 2011, 18, 1425-1433.	5.0	131
118	Element imaging in formalin fixed slices of human mesencephalon. <i>International Journal of Mass Spectrometry</i> , 2011, 307, 240-244.	0.7	21
119	Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease. <i>Brain Research</i> , 2011, 1420, 59-67.	1.1	66
121	α -Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. <i>Journal of Clinical Investigation</i> , 2011, 121, 715-725.	3.9	722
122	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. <i>Acta Neuropathologica</i> , 2011, 121, 509-517.	3.9	52
123	Glial dysfunction in the pathogenesis of α -synucleinopathies: emerging concepts. <i>Acta Neuropathologica</i> , 2011, 121, 675-693.	3.9	164
124	Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the ^{13}C -acetate breath test. <i>Journal of Neurology</i> , 2011, 258, 421-426.	1.8	69
125	The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson's disease rat model. <i>Neurological Sciences</i> , 2011, 32, 41-51.	0.9	32
126	Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. <i>Journal of Neural Transmission</i> , 2011, 118, 821-839.	1.4	156
127	Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 721-733.	2.4	73
128	Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild. <i>Movement Disorders</i> , 2011, 26, 65-72.	2.2	86
129	Electrogastrographyc activity in Parkinson's disease patients with and without motor fluctuations. <i>Movement Disorders</i> , 2011, 26, 1736-1740.	2.2	1
130	Milestones in research on the pathophysiology of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1032-1041.	2.2	170
131	Cell Transplantation and Gene Therapy in Parkinson's Disease. <i>Mount Sinai Journal of Medicine</i> , 2011, 78, 126-158.	1.9	43
132	Mouse Models of Cognitive Deficits Due to Alpha-Synuclein Pathology. <i>Journal of Parkinson's Disease</i> , 2011, 1, 217-227.	1.5	20

#	ARTICLE	IF	CITATIONS
133	α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease. <i>Pharmacological Reviews</i> , 2011, 63, 938-966.	7.1	174
134	Traumatic Brain Injury in Adult Rats Causes Progressive Nigrostriatal Dopaminergic Cell Loss and Enhanced Vulnerability to the Pesticide Paraquat. <i>Journal of Neurotrauma</i> , 2011, 28, 1783-1801.	1.7	118
135	Olfaction in <i>Parkin</i> heterozygotes and compound heterozygotes. <i>Neurology</i> , 2011, 76, 319-326.	1.5	50
136	Altered Activation Patterns within the Olfactory Network in Parkinson's Disease. <i>Cerebral Cortex</i> , 2011, 21, 1246-1253.	1.6	42
137	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. <i>Science Translational Medicine</i> , 2012, 4, 128ra41.	5.8	107
138	Genomics and Bioinformatics of Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009449-a009449.	2.9	24
139	Neuropsychological Features of Early Cognitive Impairment in Parkinson's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 84-102.	0.2	1
140	White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract-Specific Analysis. <i>American Journal of Neuroradiology</i> , 2012, 33, 890-895.	1.2	86
141	Quantitative imaging of Cu, Fe, Mn and Zn in the L-DOPA-treated unilateral 6-hydroxydopamine Parkinson's disease mouse model by LA-ICP-MS. <i>Biomedical Spectroscopy and Imaging</i> , 2012, 1, 125-136.	1.2	15
142	Depression in Parkinson's disease: diagnosis and treatment. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 617-620.	0.3	41
143	Neurotoxin-based models of Parkinson's disease. <i>Neuroscience</i> , 2012, 211, 51-76.	1.1	425
144	Living on the edge with too many mouths to feed: Why dopamine neurons die. <i>Movement Disorders</i> , 2012, 27, 1478-1483.	2.2	343
145	Ability and Reproducibility of Fourier-Domain Optical Coherence Tomography to Detect Retinal Nerve Fiber Layer Atrophy in Parkinson's Disease. <i>Ophthalmology</i> , 2012, 119, 2161-2167.	2.5	107
146	Parkinson's Disease. <i>Sub-Cellular Biochemistry</i> , 2012, 65, 389-455.	1.0	283
147	What can we expect from the serotonergic side of L-DOPA?. <i>Revue Neurologique</i> , 2012, 168, 927-938.	0.6	3
149	Therapeutic Applications of Induced Pluripotent Stem Cells in Parkinson's Disease. , 2012, , 409-420.		0
150	Olfactory dysfunctions in neurodegenerative disorders. <i>Journal of Neuroscience Research</i> , 2012, 90, 1693-1700.	1.3	40
151	Nicotine as a potential neuroprotective agent for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 947-957.	2.2	193

#	ARTICLE	IF	CITATIONS
152	Differential effect of dopa and subthalamic stimulation on vestibular activity in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1268-1275.	2.2	40
153	The significance of neuronal lateralisation in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 953-962.	1.4	55
154	The HSPB8-BAG3 chaperone complex is upregulated in astrocytes in the human brain affected by protein aggregation diseases. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 39-53.	1.8	76
155	The effects of nigrostriatal dopamine depletion on the thalamic parafascicular nucleus. <i>Brain Research</i> , 2012, 1446, 46-55.	1.1	13
156	Neurochemistry and the non-motor aspects of PD. <i>Neurobiology of Disease</i> , 2012, 46, 508-526.	2.1	73
157	Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 411-416.	1.7	38
158	Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?. <i>European Journal of Neuroscience</i> , 2012, 35, 1894-1907.	1.2	46
159	Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome study. <i>Movement Disorders</i> , 2012, 27, 406-412.	2.2	162
160	Contribution of Serotonergic Transmission to the Motor and Cognitive Effects of High-Frequency Stimulation of the Subthalamic Nucleus or Levodopa in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2012, 45, 173-185.	1.9	35
161	Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. <i>Molecular Neurodegeneration</i> , 2013, 8, 6.	4.4	25
162	Orthostatic hypotension in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2013, 3, 363-377.	1.2	1
163	Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach. <i>Journal of Neurology</i> , 2013, 260, 2951-2958.	1.8	34
164	The Role of Glia in Alpha-Synucleinopathies. <i>Molecular Neurobiology</i> , 2013, 47, 575-586.	1.9	61
165	Parkinson's Disease: a look to the future. <i>Movement Disorders</i> , 2013, 28, 1209-1209.	2.2	3
166	Retinal nerve changes in patients with tremor dominant and akinetic rigid Parkinson's disease. <i>Neurological Sciences</i> , 2013, 34, 689-693.	0.9	49
167	Remodeling of the fovea in Parkinson disease. <i>Journal of Neural Transmission</i> , 2013, 120, 745-753.	1.4	64
168	Centenary of Lewy bodies (1912-2012). <i>Journal of Neural Transmission</i> , 2013, 120, 509-516.	1.4	23
169	Mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 517-521.	1.4	14

#	ARTICLE	IF	CITATIONS
170	Parkinson's disease: Is it all in the genes?. <i>Movement Disorders</i> , 2013, 28, 1027-1029.	2.2	3
171	Inflammation and α -Synuclein's Prion-like Behavior in Parkinson's Disease—Is There a Link?. <i>Molecular Neurobiology</i> , 2013, 47, 561-574.	1.9	186
172	Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: Comparison with conventional diffusion tensor imaging. <i>Magnetic Resonance Imaging</i> , 2013, 31, 1501-1506.	1.0	76
174	Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 61-70.	1.2	2
175	Changes in properties of serine 129 phosphorylated α -synuclein with progression of Lewy-type histopathology in human brains. <i>Experimental Neurology</i> , 2013, 240, 190-204.	2.0	120
176	α -Synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. <i>Journal of Molecular Medicine</i> , 2013, 91, 693-703.	1.7	55
177	Behavioral testing regimens in genetic-based animal models of Parkinson's disease: Cogencies and caveats. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 846-859.	2.9	11
178	Activity-dependent secretion of α -synuclein by enteric neurons. <i>Journal of Neurochemistry</i> , 2013, 125, 512-517.	2.1	77
179	Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. <i>Eye</i> , 2013, 27, 507-514.	1.1	93
180	Psychosis and Parkinson's Disease. , 2013, , 75-92.		1
181	White Matter Microstructural Integrity and Executive Function in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 349-354.	1.2	34
182	Cohort Profile: A population-based cohort to study non-motor symptoms in parkinsonism (EPIPARK). <i>International Journal of Epidemiology</i> , 2013, 42, 128-128k.	0.9	32
183	What's to like about the prion-like hypothesis for the spreading of aggregated α -synuclein in Parkinson disease?. <i>Prion</i> , 2013, 7, 92-97.	0.9	63
184	Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders. <i>RSC Drug Discovery Series</i> , 2013, , 392-413.	0.2	1
186	Parkinson's disease: pathology, anatomy, and behavior. , 0, , 14-24.		0
188	Structural disorder and the loss of RNA homeostasis in aging and neurodegenerative disease. <i>Frontiers in Genetics</i> , 2013, 4, 149.	1.1	6
189	The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. <i>Frontiers in Computational Neuroscience</i> , 2013, 7, 13.	1.2	264
190	Protein Transmission, Seeding and Degradation: Key Steps for α -Synuclein Prion-Like Propagation. <i>Experimental Neurobiology</i> , 2014, 23, 324-336.	0.7	45

#	ARTICLE	IF	CITATIONS
191	Measuring Hemoglobin Levels in the Optic Disc of Parkinson's Disease Patients Using New Colorimetric Analysis Software. <i>Parkinson's Disease</i> , 2014, 2014, 1-8.	0.6	7
192	Cerebrospinal fluid α -synuclein in the differential diagnosis of parkinsonian syndromes. <i>Future Neurology</i> , 2014, 9, 525-532.	0.9	8
193	The Association of Spectral-Domain Optical Coherence Tomography Determined Ganglion Cell Complex Parameters and Disease Severity in Parkinson's Disease. <i>Current Eye Research</i> , 2014, 39, 1117-1122.	0.7	30
194	Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. <i>Journal of Clinical Movement Disorders</i> , 2014, 1, 8.	2.2	17
195	<i>Caenorhabditis elegans</i> as a model system for studying non-cell-autonomous mechanisms in protein-misfolding diseases. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 31-39.	1.2	52
196	Hippocampal Proliferation Is Increased in Presymptomatic Parkinson's Disease and due to Microglia. <i>Neural Plasticity</i> , 2014, 2014, 1-13.	1.0	20
197	Adaptation and Sensitization to Proteotoxic Stress. Dose-Response, 2014, 12, dose-response.1.	0.7	14
198	In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α -synuclein phosphorylation in mouse brain. <i>Neuroscience</i> , 2014, 256, 72-82.	1.1	40
199	Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study. <i>Journal of Neural Transmission</i> , 2014, 121, 41-47.	1.4	61
200	Increased Amoeboid Microglial Density in the Olfactory Bulb of Parkinson's and Alzheimer's Patients. <i>Brain Pathology</i> , 2014, 24, 152-165.	2.1	70
201	A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. <i>Neuroradiology</i> , 2014, 56, 251-258.	1.1	94
202	Taste performance in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014, 121, 119-122.	1.4	46
203	Neurophysiological Studies and Non-Motor Symptoms Prior to Ataxia in a Patient with Machado-Joseph Disease: Trying to Understand the Natural History of Brain Degeneration. <i>Cerebellum</i> , 2014, 13, 447-51.	1.4	12
204	Harnessing neurogenesis for the possible treatment of Parkinson's disease. <i>Journal of Comparative Neurology</i> , 2014, 522, 2817-2830.	0.9	24
205	Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 509-522.	0.5	3
206	Mitochondrial genome changes and neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1198-1207.	1.8	64
207	Development of a prediction formula of Parkinson disease severity by optical coherence tomography. <i>Movement Disorders</i> , 2014, 29, 68-74.	2.2	75
208	Role of synucleins in traumatic brain injury - An experimental in vitro and in vivo study in mice. <i>Molecular and Cellular Neurosciences</i> , 2014, 63, 114-123.	1.0	36

#	ARTICLE	IF	CITATIONS
209	Transgenic Rodent Models to Study Alpha-Synuclein Pathogenesis, with a Focus on Cognitive Deficits. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 22, 303-330.	0.8	30
211	Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. <i>Nature Medicine</i> , 2014, 20, 130-138.	15.2	547
212	Differential risks of cancer types in people with Parkinson's disease: A national record-linkage study. <i>European Journal of Cancer</i> , 2014, 50, 2456-2462.	1.3	68
213	Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. <i>Acta Neuropathologica Communications</i> , 2014, 2, 90.	2.4	140
214	Peptidoglycan recognition protein genes and risk of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1171-1180.	2.2	47
215	Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α -synuclein BAC transgenic mouse. <i>Neurobiology of Disease</i> , 2014, 62, 193-207.	2.1	46
216	Imaging of olfactory bulb and gray matter volumes in brain areas associated with olfactory function in patients with Parkinson's disease and multiple system atrophy. <i>European Journal of Radiology</i> , 2014, 83, 564-570.	1.2	55
217	Dementia – The real problem for patients with Parkinson's disease. <i>Basal Ganglia</i> , 2014, 4, 9-13.	0.3	6
218	Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. <i>Neuropharmacology</i> , 2014, 76, 97-105.	2.0	58
219	Targeting impulsivity in Parkinson's disease using atomoxetine. <i>Brain</i> , 2014, 137, 1986-1997.	3.7	116
220	Advances in non-dopaminergic treatments for Parkinson's disease. <i>Frontiers in Neuroscience</i> , 2014, 8, 113.	1.4	72
222	Mild Cognitive Impairment and Parkinson's Disease - Something to Remember. <i>Journal of Parkinson's Disease</i> , 2015, 4, 651-656.	1.5	22
223	Meanings of feeling well among women with Parkinson's disease. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2015, 10, 28730.	0.6	4
224	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 681-697.	1.5	195
225	Purine metabolism gene deregulation in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 926-940.	1.8	59
226	Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease. <i>Acta Ophthalmologica</i> , 2015, 93, e672-7.	0.6	21
227	shRNA targeting α -synuclein prevents neurodegeneration in a Parkinson's disease model. <i>Journal of Clinical Investigation</i> , 2015, 125, 2721-2735.	3.9	143
228	Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	46

#	ARTICLE	IF	CITATIONS
229	Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. <i>Heart Rhythm</i> , 2015, 12, 2285-2293.	0.3	82
230	Role of α -Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 1-19.	1.5	174
231	Parkinson's disease as a result of aging. <i>Aging Cell</i> , 2015, 14, 293-308.	3.0	165
232	Evaluation of an α -synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 922-930.	1.4	33
233	An odor identification approach based on event-related pupil dilation and gaze focus. <i>International Journal of Psychophysiology</i> , 2015, 96, 201-209.	0.5	9
234	Severe, Persistent and Fatal Delirium in Psychogeriatric Patients Admitted to a Psychiatric Hospital. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 253-264.	0.6	8
235	Selective changes of ocular vestibular myogenic potentials in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 584-589.	2.2	29
236	Heat shock protein defenses in the neocortex and allocortex of the telencephalon. <i>Neurobiology of Aging</i> , 2015, 36, 1924-1937.	1.5	15
237	In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms. <i>Clinical Autonomic Research</i> , 2015, 25, 301-307.	1.4	32
238	Distinct populations of neurons respond to emotional valence and arousal in the human subthalamic nucleus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3116-3121.	3.3	48
239	Assessing Cerebral Glucose Metabolism in Patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 2062-2069.	2.4	61
240	Association between α -synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. <i>Brain</i> , 2015, 138, 2659-2671.	3.7	69
241	Multisystem Lewy body disease and the other parkinsonian disorders. <i>Nature Genetics</i> , 2015, 47, 1378-1384.	9.4	49
242	Determinants of Selective Vulnerability of Dopamine Neurons in Parkinson's Disease. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 821-837.	0.7	0
243	Pathophysiology and clinical management of pain in Parkinson's disease: Differences in efficacy of dopamine agonists and deep brain stimulation. <i>Pain Research</i> , 2016, 31, 135-146.	0.1	0
244	Parkinsonian Balance Deficits Quantified Using a Game Industry Board and a Specific Battery of Four Paradigms. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 431.	1.0	4
245	Evaluation of Retinal Vessel Morphology in Patients with Parkinson's Disease Using Optical Coherence Tomography. <i>PLoS ONE</i> , 2016, 11, e0161136.	1.1	35
246	Classification and Characteristics of Pain Associated with Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	23

#	ARTICLE	IF	CITATIONS
247	Pain management in patients with Parkinson's disease: challenges and solutions. Journal of Multidisciplinary Healthcare, 2016, Volume 9, 469-479.	1.1	60
248	Micronutrients and Risk of Parkinson's Disease. Gerontology and Geriatric Medicine, 2016, 2, 233372141664428.	0.8	9
249	Lung Function Testing <i>On</i> and <i>Off</i> Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia. Movement Disorders Clinical Practice, 2016, 3, 146-150.	0.8	7
250	Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dual-hit hypothesis of neurodegeneration. Hippocampus, 2016, 26, 980-994.	0.9	20
251	Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson's Disease Rat Model. Journal of Parkinson's Disease, 2016, 6, 317-323.	1.5	10
252	Serum Tyrosine-to-Phenylalanine Ratio is Low in Parkinson's Disease. Journal of Parkinson's Disease, 2016, 6, 423-431.	1.5	17
253	Animal behavioral assessments in current research of Parkinson's disease. Neuroscience and Biobehavioral Reviews, 2016, 65, 63-94.	2.9	63
254	The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson's disease. Journal of the Neurological Sciences, 2016, 368, 374-378.	0.3	30
255	Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology, 2016, 42, 6-19.	1.8	67
256	Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. European Journal of Pain, 2016, 20, 151-165.	1.4	76
257	Retinal nerve fiber layer thinning: a window into rapid eye movement sleep behavior disorders in Parkinson's disease. Sleep and Breathing, 2016, 20, 1285-1292.	0.9	19
258	Beyond muscles: The untapped potential of creatine. International Immunopharmacology, 2016, 37, 31-42.	1.7	64
259	Dysphagia in Parkinson's Disease. Dysphagia, 2016, 31, 24-32.	1.0	313
260	Axonal transport and secretion of fibrillar forms of α -synuclein, A β 242 peptide and HTTExon 1. Acta Neuropathologica, 2016, 131, 539-548.	3.9	127
261	Modern treatment in Parkinson's disease, a personal approach. Journal of Neural Transmission, 2016, 123, 73-80.	1.4	21
262	Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiology of Disease, 2016, 85, 262-274.	2.1	156
263	Language Deficits as a Preclinical Window into Parkinson's Disease: Evidence from Asymptomatic Parkin and Dardarin Mutation Carriers. Journal of the International Neuropsychological Society, 2017, 23, 150-158.	1.2	62
264	Secondary nucleation of monomers on fibril surface dominates α -synuclein aggregation and provides autocatalytic amyloid amplification. Quarterly Reviews of Biophysics, 2017, 50, e6.	2.4	183

#	ARTICLE	IF	CITATIONS
266	An update on the recognition and treatment of autonomic symptoms in Parkinson's disease. Expert Review of Neurotherapeutics, 2017, 17, 791-799.	1.4	7
267	Tau/Î±-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Movement Disorders, 2017, 32, 1066-1073.	2.2	44
269	New olfactometric findings in Parkinson's disease. Clinical Otolaryngology, 2017, 42, 837-843.	0.6	14
270	Autonomic Dysfunction in Parkinson's Disease: Cardiovascular Symptoms, Thermoregulation, and Urogenital Symptoms. International Review of Neurobiology, 2017, 134, 771-785.	0.9	21
271	Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms. Archives of Medical Research, 2017, 48, 221-227.	1.5	22
272	Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Scientific Reports, 2017, 7, 11469.	1.6	52
273	Animal models of Î±-synucleinopathy for Parkinson disease drug development. Nature Reviews Neuroscience, 2017, 18, 515-529.	4.9	166
274	Structural changes in Parkinson's disease: voxel-based morphometry and diffusion tensor imaging analyses based on 123I-MIBG uptake. European Radiology, 2017, 27, 5073-5079.	2.3	6
275	Brain infusion of Î±-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice. Behavioural Brain Research, 2017, 333, 150-160.	1.2	27
276	A prospective evaluation of taste in Parkinson's disease. Journal of Neural Transmission, 2017, 124, 347-352.	1.4	13
277	Refractory megacolon in Parkinson's disease: May not only be due to autonomic dysfunction. European Geriatric Medicine, 2017, 8, 73-74.	1.2	1
278	Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated Î±-Synuclein in the Enteric Nervous System of A53T Mutant Human Î±-Synuclein Transgenic Mice. Journal of Neuro pathology and Experimental Neurology, 2017, 76, 1046-1057.	0.9	36
279	A Life-Long Approach to Physical Activity for Brain Health. Frontiers in Aging Neuroscience, 2017, 9, 147.	1.7	52
280	Multivariate Analysis of 18F-DMFP PET Data to Assist the Diagnosis of Parkinsonism. Frontiers in Neuroinformatics, 2017, 11, 23.	1.3	32
281	Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients. Parkinson's Disease, 2017, 2017, 1-14.	0.6	7
282	Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson's disease. PLoS ONE, 2017, 12, e0177163.	1.1	22
283	Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Translational Neurodegeneration, 2017, 6, 20.	3.6	104
284	Mitochondrial Respiration in Intact Peripheral Blood Mononuclear Cells and Sirtuin 3 Activity in Patients with Movement Disorders. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	8

#	ARTICLE	IF	CITATIONS
285	Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm. <i>Npj Parkinson's Disease</i> , 2018, 4, 5.	2.5	18
286	<i>Neurological Diseases</i> , 2018, 1-14.		0
287	The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2018, 109, 226-248.	2.1	214
288	Retinal Findings on OCT in Systemic Conditions. <i>Seminars in Ophthalmology</i> , 2018, 33, 525-546.	0.8	17
289	Quantification of hydrogen production by intestinal bacteria that are specifically dysregulated in Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0208313.	1.1	41
290	From Prodromal to Overt Parkinson's Disease: Towards a New Definition in the Year 2040. <i>Journal of Parkinson's Disease</i> , 2018, 8, S19-S23.	1.5	11
291	Effect of rs3910105 in the Synuclein Gene on Dopamine Transporter Availability in Healthy Subjects. <i>Yonsei Medical Journal</i> , 2018, 59, 787.	0.9	3
292	Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. <i>Journal of Parkinson's Disease</i> , 2018, 8, 303-322.	1.5	151
293	The Therapeutic Potential of Metformin in Neurodegenerative Diseases. <i>Frontiers in Endocrinology</i> , 2018, 9, 400.	1.5	203
294	On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 455.	1.1	272
295	Microglial involvement in the development of olfactory dysfunction. <i>Journal of Veterinary Science</i> , 2018, 19, 319.	0.5	16
296	Does Parkinson's disease start in the gut?. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 67-70.	0.3	11
297	Novel Approach to Stem Cell Therapy in Parkinson's Disease. <i>Stem Cells and Development</i> , 2018, 27, 951-957.	1.1	39
298	The enteric nervous system in PD: gateway, bystander victim, or source of solutions. <i>Cell and Tissue Research</i> , 2018, 373, 313-326.	1.5	19
299	Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?. <i>European Journal of Neuroscience</i> , 2019, 49, 422-439.	1.2	2
300	Alpha-synuclein: prion or prion-like?. <i>Acta Neuropathologica</i> , 2019, 138, 509-514.	3.9	14
301	Spread of α -synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. <i>Nature Neuroscience</i> , 2019, 22, 1248-1257.	7.1	187
302	Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 891-899.	0.9	44

#	ARTICLE	IF	CITATIONS
303	Cancer risk in patients with Parkinsonâ€™s disease in South Korea: A nationwide, population-based cohort study. <i>European Journal of Cancer</i> , 2019, 117, 5-13.	1.3	37
304	Î±-Synuclein pathology in Parkinsonâ€™s disease and related Î±-synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	1.0	177
305	Spreading of alphaâ€šynuclein â€“ relevant or epiphenomenon?. <i>Journal of Neurochemistry</i> , 2019, 150, 605-611.	2.1	34
306	Different Circulating Trace Amine Profiles in De Novo and Treated Parkinsonâ€™s Disease Patients. <i>Scientific Reports</i> , 2019, 9, 6151.	1.6	30
307	Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1829.	1.8	43
308	Risk of dementia after Parkinsonâ€™s disease in Taiwan: a population-based retrospective cohort study using National Health Insurance claims. <i>BMJ Open</i> , 2019, 9, e025274.	0.8	6
309	LRRK2 inhibition does not impart protection from Î±-synuclein pathology and neuron death in non-transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 28.	2.4	39
310	The center of olfactory bulbâ€šseeded Î±â€šynucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice. <i>Brain Pathology</i> , 2019, 29, 741-770.	2.1	18
311	LRRK2 modifies Î±-syn pathology and spread in mouse models and human neurons. <i>Acta Neuropathologica</i> , 2019, 137, 961-980.	3.9	142
312	Smelling Parkinsonâ€™s Disease: New Metabolomic Biomarker for PD. <i>ACS Central Science</i> , 2019, 5, 575-576.	5.3	0
313	Transmission of Î±-synuclein seeds in neurodegenerative disease: recent developments. <i>Laboratory Investigation</i> , 2019, 99, 971-981.	1.7	74
314	Topography of emotional valence and arousal within the motor part of the subthalamic nucleus in Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2019, 9, 19924.	1.6	5
317	Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. <i>Brain Pathology</i> , 2019, 29, 544-557.	2.1	33
318	Exercise as a therapeutic intervention for motor and non-motor symptoms in Parkinsonâ€™s disease: Evidence from rodent models. <i>Progress in Neurobiology</i> , 2019, 172, 2-22.	2.8	29
319	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological Î±-Synuclein Insult. <i>Neuron</i> , 2020, 105, 822-836.e7.	3.8	89
320	Characterization of novel conformation-selective Î±-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
321	Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117177.	0.3	20
322	The unfolded protein response is activated in the olfactory system in Alzheimerâ€™s disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 109.	2.4	22

#	ARTICLE	IF	CITATIONS
323	A randomized double-blind placebo-controlled multicenter trial of Bushen Yisui and Ziyin Jiangzhuo formula for constipation in Parkinson disease. <i>Medicine (United States)</i> , 2020, 99, e21145.	0.4	4
324	Test the Best: Classification Accuracies of Four Cognitive Rating Scales for Parkinson's Disease Mild Cognitive Impairment. <i>Archives of Clinical Neuropsychology</i> , 2020, 35, 1069-1077.	0.3	15
325	Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson's disease. <i>Neuropharmacology</i> , 2021, 194, 108378.	2.0	11
326	Parkinson's Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish. <i>Neuroepidemiology</i> , 2020, 54, 392-397.	1.1	1
327	Classification algorithms applied to blood-based transcriptome meta-analysis to predict idiopathic Parkinson's disease. <i>Computers in Biology and Medicine</i> , 2020, 124, 103925.	3.9	19
328	The Microbiome as a Modifier of Neurodegenerative Disease Risk. <i>Cell Host and Microbe</i> , 2020, 28, 201-222.	5.1	120
329	Calcium, Bioenergetics, and Parkinson's Disease. <i>Cells</i> , 2020, 9, 2045.	1.8	46
330	Gene specific therapies – the next therapeutic milestone in neurology. <i>Neurological Research and Practice</i> , 2020, 2, 25.	1.0	14
331	The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases. <i>Translational Neurodegeneration</i> , 2020, 9, 22.	3.6	62
332	Deficits in olfactory sensitivity in a mouse model of Parkinson's disease revealed by plethysmography of odor-evoked sniffing. <i>Scientific Reports</i> , 2020, 10, 9242.	1.6	30
333	What are the considerations for anti-hypertensive treatment in patients with Parkinson's disease?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1127-1130.	0.9	7
334	Mechanisms of alpha-synuclein toxicity: An update and outlook. <i>Progress in Brain Research</i> , 2020, 252, 91-129.	0.9	49
335	Ultrasonography of the Vagus Nerve in the Diagnosis of Parkinson's Disease. <i>Parkinson's Disease</i> , 2020, 2020, 1-4.	0.6	11
336	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. <i>Cells</i> , 2020, 9, 841.	1.8	51
337	Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2081-2094.	2.4	8
338	On the Emergence of Tremor in Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 261-269.	1.5	2
339	Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases. <i>Neurological Sciences</i> , 2021, 42, 1473-1482.	0.9	8
340	Systemic α -synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. <i>Molecular Psychiatry</i> , 2021, 26, 556-567.	4.1	24

#	ARTICLE	IF	CITATIONS
341	Lewy Body Disease. , 2021, , 18-41.		0
343	Functional connectivity of spoken language processing in early-stage Parkinson's disease: An MEG study. <i>NeuroImage: Clinical</i> , 2021, 32, 102718.	1.4	13
344	Serotonergic control of the glutamatergic neurons of the subthalamic nucleus. <i>Progress in Brain Research</i> , 2021, 261, 423-462.	0.9	3
345	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. <i>Neurobiology of Disease</i> , 2021, 149, 105229.	2.1	36
346	Sexual Disorders and Quality of Life in Parkinson's Disease. <i>Sexual Medicine</i> , 2021, 9, 100280-100280.	0.9	16
347	microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers. <i>Sleep Medicine</i> , 2021, 78, 160-168.	0.8	6
348	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. <i>Cells</i> , 2021, 10, 375.	1.8	54
349	Presynaptic accumulation of α -synuclein causes synaptopathy and progressive neurodegeneration in <i>Drosophila</i> . <i>Brain Communications</i> , 2021, 3, fcab049.	1.5	9
351	Effect of Yuzu (Citrus junos) Seed Limonoids and Spermine on Intestinal Microbiota and Hypothalamic Tissue in the Sandhoff Disease Mouse Model. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 17.	1.3	3
352	Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021, 11, 54.	1.0	31
353	Meynert nucleus-related cortical thinning in Parkinson's disease with mild cognitive impairment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 1554-1566.	1.1	13
355	Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. <i>Journal of Neurology</i> , 2022, 269, 1154-1163.	1.8	63
356	High-resolution ultrasound changes of the vagus nerve in idiopathic Parkinson's disease (IPD): a possible additional index of disease. <i>Neurological Sciences</i> , 2021, 42, 5205-5211.	0.9	12
357	Challenges in the diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2021, 20, 385-397.	4.9	468
358	Sweet or Bland Dreams? Taste Loss in Isolated REM Sleep Behavior Disorder and Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2431-2435.	2.2	2
359	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. <i>Journal of Neurochemistry</i> , 2021, 158, 1394-1411.	2.1	42
360	Self-Perception of Voice and Swallowing Handicap in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 2027-2034.	1.5	7
361	Galactin-3 Deletion Reduces LPS and Acute Colitis-Induced Pro-Inflammatory Microglial Activation in the Ventral Mesencephalon. <i>Frontiers in Pharmacology</i> , 2021, 12, 706439.	1.6	6

#	ARTICLE	IF	CITATIONS
362	Drosophila as a Model for Microbiota Studies of Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 479-490.	1.2	10
363	Parkinson's Disease and Gut Microbiota. <i>Annals of Nutrition and Metabolism</i> , 2021, 77, 28-35.	1.0	41
364	A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1555-1567.	1.5	15
365	Heat Shock Protein 70 as a Sex-Skewed Regulator of α -Synucleinopathy. <i>Neurotherapeutics</i> , 2021, 18, 2541-2564.	2.1	5
366	Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 158, 105478.	2.1	15
367	Fearing Parkinson's Disease: Relationships Between Cognition and Emotion. , 2021, , 419-430.		0
368	Immunotherapy Strategies for Lewy Body and Parkinson's Diseases. , 2009, , 599-613.		1
369	Motor Control and Dyscontrol in Sleep. , 2017, , 713-757.		1
370	Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. , 2006, , 123-132.		26
371	The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?. , 2006, , 111-117.		25
372	Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. <i>Acta Neuropathologica Communications</i> , 2014, 2, 90.	2.4	94
373	Synucleinopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 72-92.	0.4	13
374	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 38.	0.4	2
375	Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and Aging In Vivo. <i>PLoS ONE</i> , 2013, 8, e58596.	1.1	30
376	Functional Reorganization of the Locomotor Network in Parkinson Patients with Freezing of Gait. <i>PLoS ONE</i> , 2014, 9, e100291.	1.1	164
377	Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0142164.	1.1	381
378	Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study. <i>PLoS ONE</i> , 2017, 12, e0187307.	1.1	195
379	Analysis of age-related changes in psychosine metabolism in the human brain. <i>PLoS ONE</i> , 2018, 13, e0193438.	1.1	24

#	ARTICLE	IF	CITATIONS
380	Methods for Studying and Structure-Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. , 2014, , 291-374.		1
381	Automatic Extraction of the Cingulum Bundle in Diffusion Tensor Tract-specific Analysis: Feasibility Study in Parkinson's Disease with and without Dementia. Magnetic Resonance in Medical Sciences, 2013, 12, 201-213.	1.1	3
382	HEMIHYPOSMIA IN A CASE OF HEMIPARKINSONISM. Electronic Journal of General Medicine, 2004, 1, .	0.3	3
383	Proprioceptive deficits in Parkinson's disease: From clinical data to animal experimentation.. Psychology and Neuroscience, 2011, 4, 235-244.	0.5	7
384	Potential role of retina as a biomarker for progression of Parkinson's disease. International Journal of Ophthalmology, 2011, 4, 433-8.	0.5	37
385	Lentivirus-mediated Persephin over-expression in Parkinson's disease rats. Neural Regeneration Research, 2015, 10, 1814.	1.6	6
386	Advanced diffusion magnetic resonance imaging in patients with Alzheimer's and Parkinson's diseases. Neural Regeneration Research, 2020, 15, 1590.	1.6	28
387	Inhalation of hydrogen gas elevates urinary 8-hydroxy-2'-deoxyguanine in Parkinson's disease. Medical Gas Research, 2018, 8, 144.	1.2	31
388	Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. , 2017, 8, 65.		50
389	Pharmacological strategies for Parkinson's disease. Health, 2012, 04, 1153-1166.	0.1	2
390	Stimulation cérébrale profonde dans la maladie de Parkinson: effets moteurs et comportementaux. Swiss Archives of Neurology, Psychiatry and Psychotherapy, 2004, 155, 399-406.	0.2	1
391	Topographical Propagation of α -synuclein Pathology in Parkinson's Disease: Phenomenology and Hypothetical Mechanism. Experimental Neurobiology, 2009, 18, 19.	0.7	1
392	Presymptomatic and Symptomatic Stages of Intracerebral Inclusion Body Pathology in Idiopathic Parkinson's Disease. , 2005, , 475-502.		0
394	Que nous apprennent les gènes responsables des formes familiales de maladie de Parkinson ?. Bulletin De L'Academie Nationale De Medecine, 2006, 190, 485-498.	0.0	1
395	Molecular Biology of Parkinson's Disease. Nucleic Acids and Molecular Biology, 2009, , 277-289.	0.2	0
396	Cognitive Deficits in Neurodegenerative Disorders: Parkinson's Disease and Alzheimer's Disease. Advances in Neurobiology, 2011, , 243-292.	1.3	0
397	Funciones y disfunciones motoras del sueño. , 2011, , 397-435.		0
404	Mood Disorder in Parkinson's Disease. Nihon Ika Daigaku Igakkai Zasshi, 2016, 12, 78-85.	0.0	0

#	ARTICLE	IF	CITATIONS
407	ã,çãf³ãfã,ã,ã,ãf³ã,ã,ãæCE'æ^ . Journal of Otolaryngology of Japan, 2018, 121, 1043-1050.	0.1	1
409	Histone and DNA Methylome in Neurodegenerative, Neuropsychiatric and Neurodevelopmental Disorders. RNA Technologies, 2019, , 63-102.	0.2	1
410	Lewy Body Disease. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 298-321.	0.1	0
411	Gray matter correlates of progression of motor symptoms in patients with Parkinsonâ€™s disease. Annals of Movement Disorders, 2019, 2, 58.	0.3	0
412	Swallowing impairment in Parkinson's disease. , 2020, , 583-595.		0
413	Swallowing impairment in Parkinson's disease. , 2020, , 585-598.		0
415	Neuroprotective Activity of Protocatechuic Acid (3,4-Dihydroxybenzoic Acid) to Treat Parkinsonâ€™s Disease. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 2466-2471.	0.1	2
416	Mechanistic Insight from Preclinical Models of Parkinsonâ€™s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy. International Journal of Molecular Sciences, 2021, 22, 11702.	1.8	7
418	An Update on the Critical Role of Î±-Synuclein in Parkinsonâ€™s Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. Molecular Neurobiology, 2022, 59, 620-642.	1.9	21
419	Serotonin und chronische MÃ¼digkeit. , 2005, , 87-92.		0
420	Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. Perspectives in Medicinal Chemistry, 2008, 2, 41-9.	4.6	4
421	Cognitive impairment and dementia in patients with Parkinson disease. Current Topics in Medicinal Chemistry, 2009, 9, 903-12.	1.0	58
422	Conditioning Against the Pathology of Parkinson's disease. Conditioning Medicine, 2018, 1, 143-162.	1.3	6
423	Translational inhibition of Î±-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. American Journal of Neurodegenerative Disease, 2019, 8, 1-15.	0.1	11
424	Assessment of Neurodegeneration by Optical Coherence Tomography and Mini-Mental Test in Parkinson's Disease. Annals of Indian Academy of Neurology, 2019, 22, 212-216.	0.2	4
425	Muscle function alterations in a Parkinson's disease animal model: Electromyographic recordings dataset. Data in Brief, 2022, 40, 107712.	0.5	1
426	Altered gut microbiota in Parkinson's disease patients with motor complications. Parkinsonism and Related Disorders, 2022, 95, 11-17.	1.1	10
428	Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of Î±-Synuclein in the Rat Brain. Molecules, 2022, 27, 507.	1.7	6

#	ARTICLE	IF	CITATIONS
429	Ce que la neuropathologie nous a appris ces 20 dernières années sur les maladies cérébrales à expression cognitive. La Presse Médicale Formation, 2022, , .	0.1	0
430	Evaluation of oropharyngeal deglutitive pressure dynamics in patients with Parkinson's disease. American Journal of Physiology - Renal Physiology, 2022, 322, G421-G430.	1.6	5
431	Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology. Current Opinion in Neurobiology, 2022, 72, 171-177.	2.0	5
432	Microbes and Parkinson's disease: from associations to mechanisms. Trends in Microbiology, 2022, 30, 749-760.	3.5	9
433	Ambroxol reverses tau and β -synuclein accumulation in a cholinergic N370S <i>GBA1</i> mutation model. Human Molecular Genetics, 2022, 31, 2396-2405.	1.4	10
434	Characterization of a Novel Monoclonal Antibody for Serine-129 Phosphorylated β -Synuclein: A Potential Application for Clinical and Basic Research. Frontiers in Neurology, 2022, 13, 821792.	1.1	2
435	Human β -synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy. Translational Psychiatry, 2022, 12, 79.	2.4	20
436	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cellular and Molecular Life Sciences, 2022, 79, 174.	2.4	45
437	The emerging postural instability phenotype in idiopathic Parkinson disease. Npj Parkinson's Disease, 2022, 8, 28.	2.5	10
439	The NRF2-Dependent Transcriptional Regulation of Antioxidant Defense Pathways: Relevance for Cell Type-Specific Vulnerability to Neurodegeneration and Therapeutic Intervention. Antioxidants, 2022, 11, 8.	2.2	26
440	Assessment of neurodegeneration by optical coherence tomography and mini-mental test in Parkinson's disease. Annals of Indian Academy of Neurology, 2019, 22, 212.	0.2	5
443	Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Frontiers in Neurology, 2022, 13, .	1.1	16
447	Linking β -synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease. Brain Communications, 2022, 4, .	1.5	14
448	Phosphorylated α -synuclein in <i>Iba1</i> -positive macrophages in the skin of patients with Parkinson's disease. Annals of Clinical and Translational Neurology, 0, , .	1.7	4
449	Taste Impairments in a Parkinson's Disease Model Featuring Intranasal Rotenone Administration in Mice. Journal of Parkinson's Disease, 2022, 12, 1863-1880.	1.5	1
450	Alternation of the Rich-Club Organization of Individual Brain Metabolic Networks in Parkinson's Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
451	Lysosomal exocytosis releases pathogenic β -synuclein species from neurons in synucleinopathy models. Nature Communications, 2022, 13, .	5.8	28
452	Quantification of noradrenergic, dopaminergic, and tectal neurons during aging in the short-lived killifish <i>Nothobranchius furzeri</i> . Aging Cell, 2022, 21, .	3.0	14

#	ARTICLE	IF	CITATIONS
453	Alterations in Large-Scale Intrinsic Connectivity Networks in the Parkinson's Disease-Associated Cognitive Impairment Continuum: A Systematic Review. <i>Noropsikiyatri Arsivi</i> , 2022, , .	0.2	0
454	Mechanisms of development of constipation in Parkinsonâ€™s disease and therapeutic approaches. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2022, 122, 21.	0.1	0
455	Mitochondrial morphology and synaptic structure altered in the retina of parkin-deficient mice. <i>Neuroscience Letters</i> , 2022, 790, 136888.	1.0	2
456	DNA methylation signatures of Alzheimerâ€™s disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types. <i>Nature Communications</i> , 2022, 13, .	5.8	35
459	Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinsonâ€™s disease. <i>Cognitive Neurodynamics</i> , 2023, 17, 1309-1320.	2.3	2
460	Striatal-Inoculation of Î±-Synuclein Preformed Fibrils Aggravated the Phenotypes of REM Sleep without Atonia in A53T BAC-SNCA Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13390.	1.8	2
461	High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimerâ€™s and Parkinsonâ€™s disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
462	Gut Microbiota Changes and Parkinsonâ€™s Disease: What Do We Know, Which Avenues Ahead. <i>Healthy Ageing and Longevity</i> , 2023, , 257-278.	0.2	0
463	Rotenone-Induced Model of Parkinsonâ€™s Disease: Beyond Mitochondrial Complex I Inhibition. <i>Molecular Neurobiology</i> , 2023, 60, 1929-1948.	1.9	16
464	Gustatory dysfunction in patients with parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2023, .	0.2	0
465	The Consequences of GBA Deficiency in the Autophagyâ€“Lysosome System in Parkinsonâ€™s Disease Associated with GBA. <i>Cells</i> , 2023, 12, 191.	1.8	9
466	White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson's disease: results from the Ontario Neurodegenerative Diseases Research Initiative. <i>European Journal of Neurology</i> , 2023, 30, 920-933.	1.7	5
467	The unique neuropathological vulnerability of the human brain to aging. <i>Ageing Research Reviews</i> , 2023, 87, 101916.	5.0	4
469	Î±-Synuclein oligomers and fibrils: partners in crime in synucleinopathies. <i>Neural Regeneration Research</i> , 2023, 18, 2332-2342.	1.6	3
470	Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinsonâ€™s Disease Patients. <i>Brain Sciences</i> , 2023, 13, 599.	1.1	4
473	Gastrointestinal disorders in Parkinsonâ€™s disease and other Lewy body diseases. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	3
480	Toward a Dimension-Free, Pre-Emptive, Integrated Health Risk Assessment of Chemicals. , 2023, , 231-261.		0